Regular insulin, which is often used in pregnancy for the treatment of diabetes, has some drawbacks: it starts its action from 30 to 60 min after subcutaneous injection and it peaks too late (2-3 ...

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs.

Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ... The FDA approved its short-acting insulin, Fiasp (insulin aspart injection) in September, and its long-acting insulin Tresiba ...